{
    "clinical_study": {
        "@rank": "82209", 
        "acronym": "GATEWAY", 
        "arm_group": [
            {
                "arm_group_label": "Laparoscopic Roux-en-Y gastric bypass", 
                "arm_group_type": "Experimental", 
                "description": "Laparoscopic Roux-en-Y gastric bypass is one of the techniques of bariatric surgery"
            }, 
            {
                "arm_group_label": "best hypertension clinical treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "best hypertension clinical treatment will be defined according to the principal investigator description"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an unicentric phase 3 randomized controlled trial, with allocation concealment,\n      intent-to-treat analysis and mask scheme at outcome assessors level,  comparing the effect\n      of Laparoscopic Roux En Y gastric bypass  with best medical treatment on reduction of\n      hypertension medications prescription.\n\n      The study hypothesis is that gastric bypass is superior than the clinical treatment on\n      reduction the number of hypertension medications.\n\n      We also evaluate the effect of Laparoscopic Roux En Y gastric bypass on systemic\n      hypertension levels and others cardiovascular risk factors."
        }, 
        "brief_title": "GAstric Bypass to Treat obEse Patients With steAdy hYpertension", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Systemic Hypertension", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Obesity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults aged between 18 and 65 years old.\n\n          -  hypertension diagnosis defined as in use of at least 2 high blood pressure medication\n             at full doses.\n\n          -  body mass index between 30,0 and 39,9 kg/m2.\n\n        Exclusion Criteria:\n\n          -  hypertension \u2265 180/120 mmHg;\n\n          -  cerebrovascular diseases in the last 6 months.\n\n          -  Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last\n             6 months.\n\n          -  Baseline psychiatric disorders: schizophrenia, bipolar disorder, severe depression,\n             psychosis.\n\n          -  Renal diseases: diabetic nephropathy, creatinine clearance < 30 ml/min.\n\n          -  Patients with secondary hypertension except due to the sleep apnea.\n\n          -  Advanced peripheral arterial disease\n\n          -  atrophic gastritis\n\n          -  Diabetes mellitus type 1 and type 2 with HbA1 c >7,0%\n\n          -  alcoholism or use of illicit drugs\n\n          -  smokers\n\n          -  previous laparotomy\n\n          -  severe hepatic disorders\n\n          -  Pregnancy or women  not using effective contraceptive methods.\n\n          -  Recent neoplasm (< 5 years)\n\n          -  Immunosuppressant drugs\n\n          -  Unable to understanding and follow the study protocol orientations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784848", 
            "org_study_id": "IEP2013_HAS"
        }, 
        "intervention": {
            "arm_group_label": [
                "Laparoscopic Roux-en-Y gastric bypass", 
                "best hypertension clinical treatment"
            ], 
            "description": "Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery", 
            "intervention_name": "Laparoscopic Roux-en-Y gastric bypass (LRYGB)", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "high blood pressure", 
            "hypertension", 
            "bariatric surgery", 
            "Laparoscopic Roux-en-Y gastric bypass (LRYGB)", 
            "obesity"
        ], 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "contact": {
                "email": "schiavon_ca@gmail.com", 
                "last_name": "Carlos A Schiavon, MD", 
                "phone": "+5511 98116 6666"
            }, 
            "contact_backup": {
                "email": "abuehler@hcor.com.br", 
                "last_name": "Anna Buehler, PharmD, PhD", 
                "phone": "+55 11 30536611", 
                "phone_ext": "8209"
            }, 
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "zip": "04005-000"
                }, 
                "name": "Research Institute of Cardiac Hospital"
            }, 
            "investigator": {
                "last_name": "Carlos A Schiavon, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.", 
        "other_outcome": [
            {
                "description": "mean difference of change from baseline blood pressure levels using ambulatory blood pressure monitoring (ABPM)and using Sphygmomanometer blood pressure monitor", 
                "measure": "absolute change from baseline in blood pressure levels", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in corporeal weight and body mass index.", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in fasting plasm glucose level", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in HbA1c percentual", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in insulin levels", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in LDL-cholesterol level", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in HDL-cholesterol level", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in triglycerides level", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "measure": "absolute change from baseline in anthropometric measurements", 
                "safety_issue": "No", 
                "time_frame": "12 and 24 months"
            }, 
            {
                "description": "all adverse reactions reported during follow-up visits.", 
                "measure": "any adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "15 days, 1, 6, 12 and 24 months"
            }
        ], 
        "overall_contact": {
            "email": "oberwanger@hcor.com.br", 
            "last_name": "Otavio Berwanger, MD, PhD", 
            "phone": "+5511 30536611", 
            "phone_ext": "8201"
        }, 
        "overall_contact_backup": {
            "email": "abuehler@hcor.com.br", 
            "last_name": "Anna Buehler, PharmD, PhD", 
            "phone": "+5511 30536611", 
            "phone_ext": "8209"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduce at least 30% of hypertension medication prescription related to the baseline hypertension treatment at 12 months after randomization.", 
            "measure": "reduction of hypertension medication prescription", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784848"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "to reduce at least 30% of hypertension medication prescription related to the baseline hypertension treatment at 6 and 24 months.", 
            "measure": "reduction of hypertension medication prescription .", 
            "safety_issue": "No", 
            "time_frame": "6 and 24 months"
        }, 
        "source": "Hospital do Coracao", 
        "sponsors": {
            "collaborator": {
                "agency": "Ethicon Endo-Surgery", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hospital do Coracao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}